Comparable remission and health care use in real-world inflammatory bowel disease patients initiating originator biologics vs biosimilars

Figure 1 Kaplan-Meier curve for the time to first remission (among those without remission at baseline), stratified by originator biologic and biosimilar, Canadian IBD Research Consortium cohort, Canada, 2018-2024. The median time to clinical remission was 12.8 months [95% confidence interval (95%CI): 7.5-23.8 months] for originator users and 12.2 months (95%CI: 9.3-24.1 months) for biosimilar users. No significant difference in the time to achieve remission between biosimilar and originator users was detected.

Figure 2 Kaplan-Meier curve for the time to: First hospitalization and first emergency department visit, stratified by originator biologic and biosimilar, Canadian IBD Research Consortium cohort, Canada, 2018-2024. A: First hospitalization; B: First emergency department (ED) visit. The median time to first hospitalization estimated by Kaplan-Meier analysis was 30.7 months [95% confidence interval (95%CI): 12.8-52.1 months] for originator users and 51.2 months (95%CI: 24.6-72.3 months) for biosimilar users with no statistically significant difference between groups (A). The median time to first ED visit was 27.4 months (95%CI: 11.6-49.3 months) for originator users and 26.4 months (95%CI: 22.6-53.4 months) for biosimilar users (B). ED: Emergency department.